Skip to main navigation
Black Diamond Therapeutics
About
Our Vision
At a Glance
Executive Team
Board of Directors
Pipeline
Pipeline
Our Approach
Silevertinib NSCLC
Silevertinib GBM
BDTX-4933
BDTX-4876
Presentations and Publications
Patients
Clinical Trials
Expanded Access
Investors & News
Overview
Press Releases
Events & Presentations
Corporate Governance
Stock Information
SEC Filings
Analyst Coverage
Investor Resources
Join Us
Values
Careers
Event Details
« Back to list
Black Diamond Silevertinib Phase 2 Update
December 03, 2025 at 8:00 AM EST
Site - Shareholder Tools
Print Page
Print Page
E-mail Alerts
E-mail Alerts
RSS Feeds
RSS Feeds
Contact IR
Contact IR
Search
Search